中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2014年
21期
62-64
,共3页
肝动脉化疗栓塞术%射频消融术%原发性肝癌
肝動脈化療栓塞術%射頻消融術%原髮性肝癌
간동맥화료전새술%사빈소융술%원발성간암
RFA%TACE%PLC
目的:观察肝动脉化疗栓塞联合射频消融术治疗原发性大肝癌的临床效果。方法选择我院收治的86例原发性大肝癌患者,随机分为观察组和对照组各43例,对照组给予肝动脉化疗栓塞术,观察组给予肝动脉化疗栓塞联合射频消融术,比较两组治疗的临床效果。结果治疗前两组ALT、TBIL、AFP、肿瘤最大直径均无明显差异(P>0.05)。治疗后两组AFP、肿瘤最大直径均较治疗前明显改善且观察组改善程度优于对照组(均P<0.05)。治疗后观察组病情缓解率明显高于对照组(P<0.05);两组不良反应发生率无明显差异(P>0.05)。结论肝动脉化疗栓塞联合射频消融术治疗原发性大肝癌,临床效果优于单纯肝动脉化疗栓塞术,且未见不良反应增加。
目的:觀察肝動脈化療栓塞聯閤射頻消融術治療原髮性大肝癌的臨床效果。方法選擇我院收治的86例原髮性大肝癌患者,隨機分為觀察組和對照組各43例,對照組給予肝動脈化療栓塞術,觀察組給予肝動脈化療栓塞聯閤射頻消融術,比較兩組治療的臨床效果。結果治療前兩組ALT、TBIL、AFP、腫瘤最大直徑均無明顯差異(P>0.05)。治療後兩組AFP、腫瘤最大直徑均較治療前明顯改善且觀察組改善程度優于對照組(均P<0.05)。治療後觀察組病情緩解率明顯高于對照組(P<0.05);兩組不良反應髮生率無明顯差異(P>0.05)。結論肝動脈化療栓塞聯閤射頻消融術治療原髮性大肝癌,臨床效果優于單純肝動脈化療栓塞術,且未見不良反應增加。
목적:관찰간동맥화료전새연합사빈소융술치료원발성대간암적림상효과。방법선택아원수치적86례원발성대간암환자,수궤분위관찰조화대조조각43례,대조조급여간동맥화료전새술,관찰조급여간동맥화료전새연합사빈소융술,비교량조치료적림상효과。결과치료전량조ALT、TBIL、AFP、종류최대직경균무명현차이(P>0.05)。치료후량조AFP、종류최대직경균교치료전명현개선차관찰조개선정도우우대조조(균P<0.05)。치료후관찰조병정완해솔명현고우대조조(P<0.05);량조불량반응발생솔무명현차이(P>0.05)。결론간동맥화료전새연합사빈소융술치료원발성대간암,림상효과우우단순간동맥화료전새술,차미견불량반응증가。
Objective To investigate the curative effect of the radiofrequency ablation (RFA) combined with Transcatheter arterial chemoembolization (TACE) therapy in treating primary hepatic carcinoma.Methods 86 cases of primary hepatic carcinoma patients in our hospital were randomly divided into treatment group and control group with 43 cases. Control group were given TACE and treatment group were given RFA additionally. The clinical effect was observed. Results The two groups before treatment, ALT, TBIL, AFP, tumor diameter had no significant difference (P > 0.05). After treatment, two groups of AFP, tumor diameter was obviously improved and the improved observation group is better than that of control group (allP < 0.05). Remission rate of observation group was obviously higher than that of the control group after treatment (P < 0.05); No difference between the incidence of adverse reactions to the two groups (P > 0.05).Conclusion The curative effect of RFA combined with TACE therapy in treating primary hepatic carcinoma was significantly higher than using TACE alone, and the adverse reactions wasn’t increased.